VEGFA and lung adenocarcinoma: In summary, this study demonstrates that the TKI Nintedanib, an anti-VEGFA/Ang2 nanobody, but to a lesser extend also unspecific IgG can reduce BM formation, making blood vessel stabilization an attractive mechanism of BM prevention in lung adenocarcinoma.